I know this is a study from a long time ago (2022 at least feels like forever ago to me) but I’m keen to start looking more deeply at what the rates of progression are after ceasing dupilumab for #atopicdermatitis
readwise.io/reader/share...
💊 According to phase 3 data, the anti–IL-4Rα monoclonal antibody #stapokibart showed significant efficacy and favorable safety among adolescent patients with moderate to severe #AtopicDermatitis when compared to placebo. Read the full summary at the link!
www.docwirenews.com/post/stapoki...
Zhao et al. demonstrate the role of keratinocyte TRPV3 as a critical driver of IL-33-mediated mast cell recruitment and inflammation in atopic dermatitis (AD). TRPV3 knockout mice exhibited significant reductions in perivascular mast cell density. In a mouse model of AD, inhibition of TRPV3, or the upstream protease-activated receptor 2 (PAR2), reduced IL-33 expression in the epidermis. The TRPV3-IL-33 axis was further demonstrated to regulate AD-associated substance P expression and neuro-mast cell interactions.
Open Access: Epidermal PAR2-TRPV3-IL-33 Signaling Promotes Mast Cell Recruitment and Sensory Nerve-Mast Cell Interactions in #AtopicDermatitis. First authors: Jiahui Zhao, LingXuan Zhou, and Chenyu Wang ; corresponding author: Miao Jing
👉 doi.org/10.1111/all.70284
#Allergy_journal
Box plots show cardiometabolic risk scores at ages 15 and 17. Each age group compares individuals with (AD) and without (No AD) a condition. Scores range from -10 to 20, with box plots indicating median, quartiles, and outliers.
In a cohort study of children and adolescents in the UK, #AtopicDermatitis was not associated with increased early #CardiovascularRisk, suggesting routine cardiovascular screening is unlikely to benefit this population.
ja.ma/4sETKib
Sanofi Reports Positive Phase 3 Atopic Dermatitis Data: Sanofi said on Mar 28, 2026 its Phase 3 (n≈1,250) met the primary endpoint with ~64% achieving EASI-75 vs 18% placebo at Week 16 (Investing.com); full data pending. 👈 Read full analysis #Sanofi #AtopicDermatitis #Phase3 #ClinicalTrials #EASI75
JAMA Dermatology presents a research letter titled "Risk of Acne in Patients With Atopic Dermatitis Starting a JAK Inhibitor vs Th2 Cytokine Inhibitor" by Maria C. Schneeweiss text@1, text@2, Richard Wyss, text@3, text@4, and Priyanka Anand.
Among adults with #AtopicDermatitis, JAK inhibitor use was associated with more than double the 6-month risk of physician-recorded #Acne compared with Th2 cytokine inhibitor, with no difference seen for folliculitis or rosacea.
ja.ma/4d1MQ1O
In this study, Fukushima-Nomura et al. analyze the blood cytokine levels in atopic dermatitis patients to identify biomarkers that correlate with disease activity during dupilumab treatment, as measured by EASI scores. Among the cytokines analyzed, IL-22 and IL-18 retained measurable variability across various time points during treatment, demonstrating their potential as biomarkers for longitudinal monitoring.
Open Access: Interleukin-22 and Interleukin-18 as Potential Blood Biomarkers in Dupilumab-Treated #AtopicDermatitis. First author: Ayano Fukushima-Nomura; corresponding author: Hiroshi Kawasaki
Read the article here: doi.org/10.1111/all.70248
#Allergy_journal
JAMA Dermatology RCT: Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis. Population: 54 Males, 21 Females, adults with moderate to severe atopic dermatitis, Mean age, 39.8 y. Intervention: 75 Patients randomized. Findings: AE incidence was similar across all groups.
Once-daily oral ICP-332, a tyrosine kinase 2 inhibitor, showed favorable safety and significantly improved disease severity versus placebo in adults with moderate to severe #AtopicDermatitis. ja.ma/4aKOF1C
JointHealth™ express - Call for patient input on ruxolitinib (Opzelura®) for atopic dermatitis. Learn more: bit.ly/ACE_CDAPatie...
#AtopicDermatitis #PatientInput
@arthritispower.bsky.social @schroeder-uhn.bsky.social @arthritistrainees.bsky.social @arthritis-ubc.bsky.social
Early enhanced management of atopic dermatitis is associated with a lower 3-year prevalence of hen's egg and any #foodallergy. The difference is mainly attributable to a reduced history of raw egg allergy, consistent with earlier tolerance acquisition. Sustained atopic dermatitis control, growth, quality of life, and respiratory allergic outcomes are similar between intervention groups.
Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for #AtopicDermatitis on Atopic March. Corresponding authors: Kiwako Yamamoto-Hanada, Hajime Hosoi and Yukihiro Ohya
👉 doi.org/10.1111/all.70262
#Allergy_journal
普段から腹立たしい奴が乾燥時期はもっと腹立たしくなるので腹いせに擬人化
#イラスト #illust #イラストレーション #illustration #オリジナル #original #擬人化 #anthropomorphism #アトピー #atopic #atopicdermatitis #女の子 #girl
In atopic dermatitis patients, this study compares the 2-year drug survival of biologics dupilumab and tralokinumab, and JAK inhibitors abrocitinib, baricitinib, and upadacitinib.
Open Access: Drug Survival in #AtopicDermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry. Corresponding author: Lian F. van der Gang
👉 doi.org/10.1111/all.70187
#Allergy_journal
Read more articles 👉 journalallergy.com/Atopic_Dermatitis_Urticaria_and_Skin_Disease
Plasma Proteomic Profiles of #AtopicDermatitis Patients with Moderate-to-Severe #Pruritus Treated with a Single Dose of #Nemolizumab https://ow.ly/i6et50YkXMM #dermsky
Researchers discovered that certain #ImmuneCells in early-life #skin are more reactive than in adults, which may explain why #eczema often begins in #childhood.
#AtopicDermatitis #DendriticCells #AllergicInflammation
Ralph Nanan from the University of Sydney, Australia, presents their research findings published in Allergy:D. Ni and R. Nanan, “Self-Reported Racial Group-Associated Immune Signaling Differences in #AtopicDermatitis and Dupilumab Treatment,” doi.org/10.1111/all.70260
youtube.com/watch?v=zqd0JGBK5rg
Antibody Therapeutics(IF=4.5, Oxford University Press)
🎯🎯GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy
academic.oup.com/abt/article/...
#IL4Ra #IL31Ra #AtopicDermatitis #Antibody
What’s next in dermatology for 2026?
At #MauiDerm Hawaii, leading experts weigh in on emerging oral psoriasis therapies, next-gen biologics, AI in oncology, acne innovation, CSU advances, and more.
Read more: www.hcplive.com/view...
#Dermatology #Psoriasis #AtopicDermatitis #CSU
Figure 1. Instruction Page for Patients in Finalized Patient Decision Aid, Patient Decision Aid for Moderate-to-Severe Atopic Dermatitis Treatment Options: Important Things to Remember When Choosing Medicine for Your Eczema
A multi-phase qualitative study developed a staged patient decision aid for #AtopicDermatitis systemic treatment that balances simple patient-focused content and clinician-desired detail, supporting shared decision-making in adults.
ja.ma/4csdO1Z
Clinicians: Free #CME program on comorbidities in #AtopicDermatitis (AD)! Topics include the impact of comorbid conditions on AD, and strategies to improve treatment and quality of life.
Watch now: https://bit.ly/4kBmOnB
Figure 1. Instruction page for patients in Finalized Patient Decision Aid. Patient Decision Aid for Moderate-to-Severe Atopic Dermatitis Treatment Options: Important Things to Remember When Choosing Medicine for Your Eczema.
A multi-phase qualitative study developed a staged patient decision aid for #AtopicDermatitis systemic treatment that balances simple patient-focused content and clinician-desired detail, supporting shared decision-making in adults.
bit.ly/4qwCauW
Positive 52-week REZOLVE-AD data show rezpegaldesleukin, a novel Treg biologic, delivered durable improvements in moderate-to-severe atopic dermatitis with monthly or quarterly dosing.💡 #AtopicDermatitis www.hcplive.com/view...
With >9,600 patient-years of exposure, long-term data show low rates of serious AEs with upadacitinib in adolescent & adult #AtopicDermatitis patients, consistent with background incidence rates.
www.hcplive.com/view...
The Surprising Link Between Sleep Disturbance and Atopic Dermatitis (AD) onlinemarketingscoops.com/2026/02/03/s...
.
#atopicdermatitis #eczema #skinhealth #healthyskin #Dermatology #skincare #EczemaRelief #AtopicSkin #itchyskin #skincondition #wellness #allergies
Positive topline data from the phase 2 INTEGUMENT-INFANT study suggest roflumilast cream 0.05% was safe, well-tolerated, and clinically active in infants with #AtopicDermatitis as young as 3 months.
🔗 www.hcplive.com/view...
A commentary by Richard Gallo: "Drugs and Bugs in Atopic Dermatitis: Benefits to the Skin Microbiome from Targeted Immunotherapies" https://doi.org/10.1016/j.jid.2025.08.001 #JIDJournal #DermatologyJournal #dermatology #dermresearch #dermscience #dermatologyresearch #skin #atopicdermatitis #dermsky
JAMA Dermatology 'Research Letter': 'Risk of Acne in Patients With Atopic Dermatitis Starting a JAK Inhibitor vs Th2 Cytokine Inhibitor' by Maria C. Schneeweiss et al. Published Online: January 21, 2026.
Among adults with #AtopicDermatitis, JAK inhibitor use was associated with more than double the 6-month risk of physician-recorded #Acne compared with Th2 cytokine inhibitor, with no difference seen for folliculitis or rosacea. ja.ma/4sYz6dt
#Sanofi has said it will press ahead with #regulatoryfilings for #atopicdermatitis (AD) candidate #amlitelimab after reporting positive data in two more phase 3 trials.
Proud moment seeing today’s Sanofi (Kymab) announcement on #amlitelimab in #atopicdermatitis and fortunate to have contributed to the early development and first patent behind this program in AD www.sanofi.com/en/media-roo...
JAMA Dermatology study: "RCT: Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis." 75 patients randomized. The AE incidence: Placebo: 17 of 25 patients (68%), ICP-332, 80 mg: 19 of 25 patients (76%), ICP-332, 120 mg: 18 of 24 patients (75%).
Once-daily oral ICP-332, a tyrosine kinase 2 inhibitor, showed favorable safety and significantly improved disease severity versus placebo in adults with moderate to severe #AtopicDermatitis.
ja.ma/45ZPrET
